{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:05:39Z","timestamp":1779318339301,"version":"3.51.4"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>\n                    Adipositas ist eine chronische Erkrankung mit einer Vielzahl an metabolischen, mechanischen und psychosozialen Komplikationen und einem hohen Risiko, an Pr\u00e4diabetes bzw. in weiterer Folge an Diabetes mellitus Typ\u00a02 zu erkranken. Sowohl die Wahl der antidiabetischen Therapie als auch der Begleittherapien nimmt vermehrt auf das Vorliegen der Adipositas R\u00fccksicht. Die modernen GLP-1-Analoga sowie der kombinierte GIP\/GLP-1-Agonist Tirzepatid nehmen einen wichtigen Stellenwert in der gemeinsamen Behandlung von Adipositas und Diabetes mellitus Typ\u00a02 ein. Die metabolische Chirurgie ist derzeit bei an Diabetes mellitus Typ\u00a02 erkrankten Menschen mit einem BMI &gt;\u202f30\u202fkg\/m\n                    <jats:sup>2<\/jats:sup>\n                    indiziert, kann zur Diabetesremission beitragen, muss jedoch in ein entsprechendes, lebenslanges Betreuungskonzept eingebunden sein. Die Lebensstilmodifikation ist die Grundlage jeder Adipositastherapie. Aufgrund der Vielzahl an neuen Medikamenten sowie der vielen neuen Studien, bei denen versucht wurde, die relevantesten zu zitieren, erfolgten gro\u00dfe \u00c4nderungen in diesem Kapitel im Vergleich zu 2023. Auch die Indikationen f\u00fcr eine metabolische Therapie wurden angepasst.\n                  <\/jats:p>","DOI":"10.1007\/s00508-026-02706-y","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:14:47Z","timestamp":1779315287000},"page":"178-185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adipositas und Diabetes mellitus Typ\u00a02 (Update 2026)","Obesity and type\u00a02 diabetes mellitus (Update 2026)"],"prefix":"10.1007","volume":"138","author":[{"given":"Johanna M.","family":"Brix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Clodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Harreiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Hoppichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian W.","family":"Kiefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca-Karla","family":"Itariu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Parzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Resl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Toplak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Wascher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Ludvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2706_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.amepre.2021.10.020","volume":"62","author":"KI Galaviz","year":"2022","unstructured":"Galaviz\u00a0KI, et\u00a0al. Interventions for reversing prediabetes: a systematic review and meta-analysis. Am J Prev Med. 2022;62:614\u201325.","journal-title":"Am J Prev Med"},{"key":"2706_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies\u00a0MJ, NN8022-1922 Study Group, et\u00a0al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314:687\u201399.","journal-title":"JAMA"},{"key":"2706_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11695-016-2457-9","volume":"27","author":"F Rubino","year":"2017","unstructured":"Rubino\u00a0F, Delegates of the 2nd Diabetes Surgery Summit, et\u00a0al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Obes Surg. 2017;27:2\u201321.","journal-title":"Obes Surg"},{"issue":"10","key":"2706_CR4","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff\u00a0AM, et\u00a0al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958\u201371.","journal-title":"N Engl J Med"},{"key":"2706_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","volume":"391","author":"ME Lean","year":"2018","unstructured":"Lean\u00a0ME, et\u00a0al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster randomised trial. Lancet. 2018;391:541\u201351.","journal-title":"Lancet"},{"key":"2706_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","volume":"7","author":"MEJ Lean","year":"2019","unstructured":"Lean\u00a0MEJ, et\u00a0al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2\u2011year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7:344\u201355.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2706_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1056\/NEJMoa1600869","volume":"376","author":"PR Schauer","year":"2017","unstructured":"Schauer\u00a0PR, et\u00a0al. Bariatric surgery versus intensive medical therapy for diabetes\u20145-year outcomes. N Engl J Med. 2017;376(7):641\u201351.","journal-title":"N Engl J Med"},{"key":"2706_CR8","unstructured":"EUROSTAT. Overweight and obesity - BMI statistics. European healthy survey 2024."},{"issue":"9669","key":"2706_CR9","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","volume":"373","author":"Prospective Studies Collaboration","year":"2009","unstructured":"Prospective Studies Collaboration, et\u00a0al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083\u201396.","journal-title":"Lancet"},{"issue":"3","key":"2706_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMp068177","volume":"356","author":"P Hossain","year":"2007","unstructured":"Hossain\u00a0P, et\u00a0al. Obesity and diabetes in the developing world - a growing challenge. N Engl J Med. 2007;356(3):213\u20135.","journal-title":"N Engl J Med"},{"issue":"9","key":"2706_CR11","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S0895-4356(01)00350-X","volume":"54","author":"NB Oldridge","year":"2001","unstructured":"Oldridge\u00a0NB, et\u00a0al. Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults. J\u00a0Clin Epidemiol. 2001;54(9):928\u201334.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2706_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000350627","volume":"6","author":"G Fruhbeck","year":"2013","unstructured":"Fruhbeck\u00a0G, et\u00a0al. Obesity: the gateway to ill health\u2014an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts. 2013;6(2):117\u201320.","journal-title":"Obes Facts"},{"key":"2706_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","volume":"405","author":"GBD 2021 Adult BMI Collaborators*","year":"2025","unstructured":"GBD 2021 Adult BMI Collaborators*. Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405:813\u201338.","journal-title":"Lancet"},{"key":"2706_CR14","unstructured":"WHO. Obesity Fact Sheet. 2025."},{"key":"2706_CR15","volume-title":"Obesity, preventing and managing the global epidemic: report of a WHO consultation on obesity","author":"World Health Organization","year":"1997","unstructured":"World Health Organization. Obesity, preventing and managing the global epidemic: report of a WHO consultation on obesity. Geneva, Switzerland: World Health Organization; 1997."},{"issue":"2","key":"2706_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/ijo.2011.100","volume":"36","author":"J Gomez-Ambrosi","year":"2012","unstructured":"Gomez-Ambrosi\u00a0J, et\u00a0al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes. 2012;36(2):286\u201394.","journal-title":"Int J Obes"},{"issue":"4","key":"2706_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ageing\/afq034","volume":"39","author":"AJ Cruz-Jentoft","year":"2010","unstructured":"Cruz-Jentoft\u00a0AJ, et\u00a0al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412\u201323.","journal-title":"Age Ageing"},{"issue":"5","key":"2706_CR18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1532-5415.2007.01140.x","volume":"55","author":"MJ Delmonico","year":"2007","unstructured":"Delmonico\u00a0MJ, et\u00a0al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J\u00a0Am Geriatr Soc. 2007;55(5):769\u201374.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"2706_CR19","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/gerona\/61.10.1059","volume":"61","author":"BH Goodpaster","year":"2006","unstructured":"Goodpaster\u00a0BH, et\u00a0al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J\u00a0Gerontol A Biol Sci Med Sci. 2006;61(10):1059\u201364.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"Suppl 6","key":"2706_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s00508-023-02270-9","volume":"135","author":"JM Brix","year":"2023","unstructured":"Brix\u00a0JM, Andersen\u00a0B, Aydinkoc-Tuzcu\u00a0K, et\u00a0al. \u00dcbergewicht und Adipositas bei Erwachsenen: allgemeine Behandlungsgrunds\u00e4tze und konservatives Management [Overweight and obesity in adults: general principles of treatment and conservative management]. Wien Klin Wochenschr. 2023;135(Suppl 6):706\u201320.","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"2706_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.mayocp.2013.11.011","volume":"89","author":"JR Cerhan","year":"2014","unstructured":"Cerhan\u00a0JR, Moore\u00a0SC, Jacobs\u00a0EJ, et\u00a0al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc. 2014;89(3):335\u201345.","journal-title":"Mayo Clin Proc"},{"key":"2706_CR22","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy\u00a0SM, et\u00a0al. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung and Blood Institute scientific statement. Circulation. 2005;112:2735\u201352.","journal-title":"Circulation"},{"issue":"9403","key":"2706_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"WHO Expert Consultation","year":"2004","unstructured":"WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157\u201363.","journal-title":"Lancet"},{"key":"2706_CR24","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KGMM Alberti","year":"2009","unstructured":"Alberti\u00a0KGMM, et\u00a0al. Harmonizing the Metabolic Syndrome, A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640\u20135.","journal-title":"Circulation"},{"issue":"1","key":"2706_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/15438627.2018.1502183","volume":"28","author":"AM Nevill","year":"2020","unstructured":"Nevill\u00a0AM, Stewart\u00a0AD, Olds\u00a0T, et\u00a0al. A new waist-to-height ratio predicts abdominal adiposity in adults. Res Sports Med. 2020;28(1):15\u201326.","journal-title":"Res Sports Med"},{"issue":"5","key":"2706_CR26","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/oby.2011.367","volume":"20","author":"LK Micklesfield","year":"2012","unstructured":"Micklesfield\u00a0LK, Goedecke\u00a0JH, Punyanitya\u00a0M, et\u00a0al. Dual-energy X\u2011ray performs as well as clinical computed tomography for the measurement of visceral fat. Obesity (Silver Spring). 2012;20(5):1109\u201314.","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"2706_CR27","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.eprac.2025.07.017","volume":"31","author":"K Nadolsky","year":"2025","unstructured":"Nadolsky\u00a0K, et\u00a0al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity\/Adiposity-Based Chronic Disease - 2025 Update. Endocr Pract. 2025;31(11):1351\u201394.","journal-title":"Endocr Pract"},{"issue":"5","key":"2706_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/1557988314567223","volume":"10","author":"SA Tsai","year":"2016","unstructured":"Tsai\u00a0SA, et\u00a0al. Gender differences in weight-related attitudes and behaviors among overweight and obese adults in the United States. Am J Mens Health. 2016;10(5):389\u201398.","journal-title":"Am J Mens Health"},{"issue":"1","key":"2706_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000373905","volume":"8","author":"C Grebitus","year":"2015","unstructured":"Grebitus\u00a0C, Hartmann\u00a0M, Reynolds\u00a0N. Global obesity study on drivers for weight reduction strategies. Obes Facts. 2015;8(1):77\u201386.","journal-title":"Obes Facts"},{"issue":"12","key":"2706_CR30","first-page":"2082","volume":"24","author":"M Otto","year":"2014","unstructured":"Otto\u00a0M, et\u00a0al. Handgrip strength as a predictor for post bariatric body composition. ObesSurg. 2014;24(12):2082\u20138.","journal-title":"ObesSurg"},{"issue":"2","key":"2706_CR31","doi-asserted-by":"publisher","first-page":"S392","DOI":"10.2337\/dc09-S346","volume":"32","author":"V Hainer","year":"2009","unstructured":"Hainer\u00a0V, Toplak\u00a0H, Stich\u00a0V. Fat or fit: what is more important? Diabet Care. 2009;32(2):S392\u2013S7.","journal-title":"Diabet Care"},{"issue":"8","key":"2706_CR32","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/j.1532-5415.2009.02366.x","volume":"57","author":"PM Cawthon","year":"2009","unstructured":"Cawthon\u00a0PM, et\u00a0al. Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? J\u00a0Am Geriatr Soc. 2009;57(8):1411\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"2706_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.7326\/0003-4819-151-5-200909010-00004","volume":"151","author":"K Esposito","year":"2009","unstructured":"Esposito\u00a0K, et\u00a0al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann InternMed. 2009;151(5):306\u201314.","journal-title":"Ann InternMed"},{"issue":"4","key":"2706_CR34","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/oby.2008.637","volume":"17","author":"TA Wadden","year":"2009","unstructured":"Wadden\u00a0TA, et\u00a0al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring). 2009;17(4):713\u201322.","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"2706_CR35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41430-020-00783-4","volume":"75","author":"M Halle","year":"2021","unstructured":"Halle\u00a0M, et\u00a0al. Meal replacement by formula diet reduces weight more than a lifestyle intervention alone in patients with overweight or obesity and accompanied cardiovascular risk factors-the ACOORH trial. Eur J Clin Nutr. 2021;75(4):661\u20139.","journal-title":"Eur J Clin Nutr"},{"issue":"5","key":"2706_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41574-022-00638-x","volume":"18","author":"KA Varady","year":"2022","unstructured":"Varady\u00a0KA, et\u00a0al. Clinical application of intermittent fasting for weight loss: progress and future directions. Nat Rev Endocrinol. 2022;18(5):309\u201321.","journal-title":"Nat Rev Endocrinol"},{"issue":"26","key":"2706_CR37","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1056\/NEJMra1905136","volume":"381","author":"R de Cabo","year":"2019","unstructured":"de Cabo\u00a0R, et\u00a0al. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. 2019;381(26):2541\u201351.","journal-title":"N Engl J Med"},{"issue":"2","key":"2706_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2337\/dc22-1622","volume":"46","author":"A Obermayer","year":"2023","unstructured":"Obermayer\u00a0A, et\u00a0al. Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)-A Randomized Controlled Trial. Diabetes Care. 2023;46(2):463\u20138.","journal-title":"Diabetes Care"},{"issue":"10322","key":"2706_CR39","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","volume":"399","author":"I Lingvay","year":"2022","unstructured":"Lingvay\u00a0I, et\u00a0al. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394\u2013405.","journal-title":"Lancet"},{"key":"2706_CR40","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1001\/jama.2012.67929","volume":"308","author":"EW Gregg","year":"2012","unstructured":"Gregg\u00a0EW, et\u00a0al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308:2489\u201396.","journal-title":"JAMA"},{"key":"2706_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"RR Wing","year":"2013","unstructured":"Wing\u00a0RR, et\u00a0al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145\u201354.","journal-title":"N Engl J Med"},{"key":"2706_CR42","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","volume":"4","author":"EW Gregg","year":"2016","unstructured":"Gregg\u00a0EW, et\u00a0al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4:913\u201321.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2706_CR43","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2213-8587(23)00385-6","volume":"12","author":"M Lean","year":"2024","unstructured":"Lean\u00a0M, et\u00a0al. 5\u2011year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. The Lancet Diabetes & Endocrinology. 2024;12(4):233\u201346.","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"2706_CR44","doi-asserted-by":"crossref","unstructured":"McGowan B et\u00a0al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nat Med. 2025 Oct 2","DOI":"10.1038\/s41591-025-03765-w"},{"issue":"Suppl 5","key":"2706_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00508-025-02568-w","volume":"137","author":"JM Brix","year":"2025","unstructured":"Brix\u00a0JM, et\u00a0al. Konsensuspapier der \u00d6sterreichischen Adipositasgesellschaft (\u00d6AG). Wien Klin Wochenschr. 2025;137(Suppl 5):167\u2013217.","journal-title":"Wien Klin Wochenschr"},{"issue":"6","key":"2706_CR46","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias\u00a0JP, et\u00a0al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"10402","key":"2706_CR47","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey\u00a0WT, et\u00a0al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613\u201326.","journal-title":"Lancet"},{"issue":"10300","key":"2706_CR48","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik\u00a0B, et\u00a0al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583\u201398.","journal-title":"Lancet"},{"issue":"1","key":"2706_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne\u00a0LJ, et\u00a0al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26\u201336.","journal-title":"N Engl J Med"},{"issue":"10278","key":"2706_CR50","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies\u00a0M, et\u00a0al. Semaglutide 2.4\u202fmg once a\u00a0week in adults with overweight or obesity, and type\u00a02 diabetes (STEP\u00a02): a\u00a0randomised, double-blind, double-dummy, placebo controlled, phase\u00a03\u00a0trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"issue":"9","key":"2706_CR51","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","volume":"12","author":"BM McGowan","year":"2024","unstructured":"McGowan\u00a0BM, et\u00a0al. Efficacy and safety of once-weekly semaglutide 2\u00b74\u202fmg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024;12(9):631\u201342.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"2706_CR52","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber\u00a0D, et\u00a0al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245\u201357.","journal-title":"N Engl J Med"},{"issue":"24","key":"2706_CR53","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff\u00a0AM, et\u00a0al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"10077","key":"2706_CR54","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux\u00a0CW, et\u00a0al. 3\u00a0years of liraglutide versus placebo for type\u00a02 diabetes risk reduction and weight management in individuals with prediabetes: a\u00a0randomised, double-blind trial. Lancet. 2017;389(10077):1399\u2013409.","journal-title":"Lancet"},{"key":"2706_CR55","unstructured":"European Medical Agency. Saxenda EPAR Product Information, 7\/2025. letzter Zugriff: September 2025."},{"issue":"4","key":"2706_CR56","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.gtc.2016.07.010","volume":"45","author":"Z Cruz-Monserrate","year":"2016","unstructured":"Cruz-Monserrate\u00a0Z, et\u00a0al. The Impact of Obesity on Gallstone Disease, Acute Pancreatitis, and Pancreatic Cancer. Gastroenterol Clin North Am. 2016;45(4):625\u201337.","journal-title":"Gastroenterol Clin North Am"},{"key":"2706_CR57","unstructured":"European Medical Agency. Xenical EPAR Product Information, 05\/2023. letzter Zugriff: Oktober 2025"},{"key":"2706_CR58","unstructured":"European Medical Agency. Mysimba EPAR Product Information, 1\/2025. letzter Zugriff: Oktober 2025."},{"issue":"5","key":"2706_CR59","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1464-5491.2004.01474.x","volume":"22","author":"C Berne","year":"2005","unstructured":"Berne\u00a0C, et\u00a0al. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med. 2005;22(5):612\u20138.","journal-title":"Diabet Med"},{"issue":"12","key":"2706_CR60","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.2337\/dc13-0234","volume":"36","author":"P Hollander","year":"2013","unstructured":"Hollander\u00a0P, et\u00a0al. Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022\u20139.","journal-title":"Diabetes Care"},{"issue":"6","key":"2706_CR61","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2337\/dc16-0236","volume":"39","author":"F Rubino","year":"2016","unstructured":"Rubino\u00a0F, et\u00a0al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39(6):861\u201377.","journal-title":"Diabetes Care"},{"issue":"26","key":"2706_CR62","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1056\/NEJMoa035622","volume":"351","author":"L Sjostrom","year":"2004","unstructured":"Sjostrom\u00a0L, et\u00a0al. Lifestyle, diabetes, and cardiovascular risk factors 10\u00a0years after bariatric surgery. N Engl J Med. 2004;351(26):2683\u201393.","journal-title":"N Engl J Med"},{"issue":"11","key":"2706_CR63","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1210\/jc.2008-1641","volume":"93","author":"WJ Pories","year":"2008","unstructured":"Pories\u00a0WJ. Bariatric surgery: risks and rewards. J\u00a0Clin Endocrinol Metab. 2008;93(11):89\u201396.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2706_CR64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/joim.12012","volume":"273","author":"L Sjostrom","year":"2013","unstructured":"Sjostrom\u00a0L. Review of the key results from the Swedish obese subjects (SOS) trial\u2014a prospective controlled intervention study of bariatric surgery. J\u00a0Intern Med. 2013;273(3):219\u201334.","journal-title":"J Intern Med"},{"issue":"11","key":"2706_CR65","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/2012.jama.11792","volume":"308","author":"M Neovius","year":"2012","unstructured":"Neovius\u00a0M, et\u00a0al. Health care use during 20 years following bariatric surgery. JAMA. 2012;308(11):1132\u201341.","journal-title":"JAMA"},{"issue":"Suppl 6","key":"2706_CR66","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00508-023-02271-8","volume":"135","author":"DM Felsenreich","year":"2023","unstructured":"Felsenreich\u00a0DM, et\u00a0al. Indikation und pr\u00e4operative Planung zur bariatrischen Operation [Indications and preoperative planning for bariatric surgery]. Wien Klin Wochenschr. 2023;135(Suppl 6):721\u20138.","journal-title":"Wien Klin Wochenschr"},{"issue":"Suppl 6","key":"2706_CR67","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00508-023-02272-7","volume":"135","author":"V Parzer","year":"2023","unstructured":"Parzer\u00a0V, et\u00a0al. Postoperatives Management [Postoperative management]. Wien Klin Wochenschr. 2023;135(Suppl 6):729\u201342.","journal-title":"Wien Klin Wochenschr"},{"issue":"7","key":"2706_CR68","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s00125-015-3591-y","volume":"58","author":"K Sjoholm","year":"2015","unstructured":"Sjoholm\u00a0K, et\u00a0al. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish obese subjects (SOS) study. Diabetologia. 2015;58(7):1448\u201353.","journal-title":"Diabetologia"},{"issue":"26","key":"2706_CR69","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1056\/NEJMoa035622","volume":"351","author":"L Sjostrom","year":"2004","unstructured":"Sjostrom\u00a0L, et\u00a0al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683\u201393.","journal-title":"N Engl J Med"},{"issue":"3","key":"2706_CR70","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.amjmed.2008.09.041","volume":"122","author":"H Buchwald","year":"2009","unstructured":"Buchwald\u00a0H, et\u00a0al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248\u2013256.e5.","journal-title":"Am J Med"},{"issue":"14","key":"2706_CR71","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1001\/jama.292.14.1724","volume":"292","author":"H Buchwald","year":"2004","unstructured":"Buchwald\u00a0H, et\u00a0al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724\u201337.","journal-title":"JAMA"},{"issue":"Suppl 6","key":"2706_CR72","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00508-023-02273-6","volume":"135","author":"R Kruschitz","year":"2023","unstructured":"Kruschitz\u00a0R, et\u00a0al. Pr\u00e4vention und Management von postinterventioneller Gewichtszunahme [Prevention and management of postinterventional weight regain]. Wien Klin Wochenschr. 2023;135(Suppl 6):743\u201350.","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"2706_CR73","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41366-024-01461-2","volume":"49","author":"N \u00c7al\u0131k Ba\u015faran","year":"2025","unstructured":"\u00c7al\u0131k Ba\u015faran\u00a0N, et\u00a0al. Post metabolic bariatric surgery weight regain: the importance of GLP\u20111 levels. Int J Obes (Lond). 2025;49(3):412\u20137.","journal-title":"Int J Obes (Lond)"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02706-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-026-02706-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02706-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:14:50Z","timestamp":1779315290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-026-02706-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":73,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2706"],"URL":"https:\/\/doi.org\/10.1007\/s00508-026-02706-y","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.\u00a0Brix hat von folgenden Unternehmen, die z.\u202fT. auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk. M.\u00a0Clodi hat f\u00fcr Vortr\u00e4ge, Studien und Beratung Honorare von Novo Nordisk, Elli Lilly, Boehringer Ingelheim, AstraZeneca, Novartis, Daiichi Sankyo, Amgen, W\u00f6rwag, Sanofi, Amarin, Roche, Bayer erhalten. J.\u00a0Harreiter hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Ultragenyx. F.\u00a0Hoppichler hat von folgenden Unternehmen, die z.\u202fT. auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Beratungs- oder Vortragst\u00e4tigkeit erhalten: Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi. F.W.\u00a0Kiefer hat von folgenden Unternehmen, die z.\u202fT. auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Beratungs- oder Vortragst\u00e4tigkeit erhalten: Eli Lilly und Novo Nordisk. B.K.\u00a0Itariu wurde f\u00fcr Beratungs- und Vortragst\u00e4tigkeit von Amgen, Boehringer Ingelheim, Novo Nordisk und Eli Lilly honoriert. V.\u00a0Parzer hat von folgenden Unternehmen, die z.\u202fT. auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Beratungs- oder Vortragst\u00e4tigkeit erhalten: Eli Lilly und Novo Nordisk. M.\u00a0Resl hat von folgenden Unternehmen, die z.\u202fT. auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Boehringer Ingelheim, Eli Lilly, Dexcom, Abbott, Roche, Bayer. K.\u00a0Schindler hat keine Interessenkonflikte anzugeben. H.\u00a0Toplak gibt Unterst\u00fctzung klinischer Studien und medizinischer Beirat sowie Referentenhonorare durch Novo Nordisk an, Honorare f\u00fcr medizinische Beratung durch Kwizda. T.C.\u00a0Wascher Honorare f\u00fcr Fortbildung und Beratung von Novo Nordisk und Eli Lilly. B.\u00a0Ludvik hat von folgenden Unternehmen, die z.\u202fT. auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Novo Nordisk.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}